Almac Group

The Almac Group is an established contract development and manufacturing organisation that provides the most unique range of integrated drug development services available to the pharmaceutical & biotech industry.

We are a privately owned organisation that has organically grown over 50 years and now employs in excess of 5,000 high skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with 17 global facilities across Europe, USA and Asia.

Our quality, innovation and efficiency are testament to the fact that over 600 companies worldwide trust Almac for their Chemical, Pharmaceutical and Clinical Development needs.

Addressing the increasing pressure for Biopharma companies to bring their clinical candidates through their pipeline faster, more efficiently and at a lower cost, Almac provides an integrated CMC service, bridging the gap between drug substance and drug product development.

As an established provider of both drug substance (advanced intermediates and Active Pharmaceutical Ingredients – small molecules and peptides) and drug product development services, and by offering these within an integrated package, our client partners are assured of scientific continuity from a dedicated project team, resulting in significant savings in both time and costs.

Charnwood Molecular

Operating from state-of-the-art research facilities in Loughborough and BioCity Nottingham, UK, we are a leading Contract Research Organisation, providing medicinal and synthetic chemistry services to the global pharmaceutical, biotechnology and chemical industries.

The cornerstone of our success is built upon regular and open communication with our clients, the highest integrity in our business relationships, high quality yet cost effective services, and the flexibility that we offer – we can undertake projects from one week in duration to multi-year, multi-FTE collaborations. Our goal is to support you in producing excellence in your own research, achieving your milestones and business objectives on time and to budget.

We offer a range of competitively priced services tailored to the specific requirements of our clients. These include Medicinal Chemistry and Contract Research (FTE). 

Medicinal Chemistry
Charnwood Molecular offers support to drug discovery efforts within the pharmaceutical and biotechnology industries. This service covers Lead Discovery and Lead Optimisation. Our pharma-trained medicinal chemists have experience in many therapeutic areas.

Contract Research
Presented with a target molecule with little or no literature precedent, we will investigate potential methods of preparation, optimisation and scale-up, according to your needs.

Company Type
Twitter Account
@charnwoodmol

Eurofins Selcia

Selcia, now part of Eurofins, is a global leader in 14C custom radiolabelling, stable isotope labelling and analytical services. With many years of experience our team of expert synthetic radiochemists can prepare radiolabelled molecules of almost any complexity for use in regulatory studies by the life sciences and chemical industries to understand: preclinical and clinical drug metabolism, human mass balance (GMP 14C Radiolabelled API), dermal penetration, tissue distribution and environmental fate. Selcia also offers GLP NMR and analytical problem solving services to support regulatory submissions, as well as the profiling and synthesis of metabolites and process impurities.  www.selcia.com 

 

  • 14C Custom Radiolabelling for pre-clinical studies (ADME, Dermal Penetration, E-fate)  
  • GMP Radiolabelled API for Clinical Trials , 14C-API for hAME and mass balance  
  • Stable Labelling  (13C, 2H, 15N) Internal Standards, Metabolites and Impurities  
  • GLP Analysis Certification and Problem Solving including GLP NMR 

 

Radiolabelling to support Life Sciences: • Metabolism • Distribution • Mass Balance • Micro-dosing • Environmental fate • Dermal Penetration 

Company Type
Keywords
Twitter Account
@SelciaLtd

Fusion Antibodies

Fusion Antibodies is a CMO that offers a range of services covering all stages of therapeutic and diagnostic antibody development from target discovery to delivery of lead optimized commercial candidates suitable for cGMP scale up.

Fusion provides contract services include...

- Antibody Humanization services
- Antibody Engineering Services
- Antibody sequencing Services
- Protein Expression & Purification Services
- Monoclonal Antibody services BLAST & Standard
- cGMP Services

The Journey to IPO


Company Type
Twitter Account
@FsnAntibodies

Isogenica

Isogenica is at the forefront of synthetic biology, pursuing a mission to provide the fastest, most efficient engine for therapeutic antibody discovery. Isogenica is developing LlamdA™ (single domain VHH) and Alexandria™ (human Fab) therapeutic antibodies based on its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process.

Quotient Sciences

Quotient Sciences is a drug development and manufacturing accelerator providing integrated services across the entire development pathway. Everything we do is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast.

Scendea

Scendea was founded as a result of a management buyout of the product development and regulatory consulting function of a clinical research organisation. Our origin dates back over 20 years, with involvement in over 1,000 development programmes.

Scendea’s expert team delivers strategic and operational support in the fields of quality/CMC, non-clinical/toxicology, clinical/medical and regulatory to successfully guide products from early development to marketing approval. 

A combination of scientific excellence, industry experience, commercial awareness and a collaborative approach allow our expert team to solve complex issues associated with medicinal product development. Scendea has team members based in the UK, Ireland, the Netherlands and the US, who deliver innovative and high-quality solutions aligned to jurisdiction-specific regulatory requirements.

At Scendea we collaborate, innovate, and together with our clients, we succeed.

Company Type
Twitter Account
@scendea

Sygnature Discovery

Sygnature Discovery is a leading independent integrated drug discovery and pre-clinical services CRO. Founded in 2004 and private equity-backed since 2017, we operate a fully-enabled research facilities in Nottingham and Alderley Park, UK housing over 500 staff (80% of our scientists have PhDs). Our experienced R&D scientists possess all the professional skills and know-how required to undertake the most demanding of drug discovery and/or pre-clinical development projects and drive them from target validation, through hit identification, hit-to-lead and lead optimization to development candidate. Sygnature collaborates with its partners via risk share and FTE-based collaborations.

Worldwide Clinical Trials

Worldwide Clinical Trials provides drug development services from Early Phase & Bioanalytical Sciences, through Phase II, III & IV

Company Type
Twitter Account
@worldwidetrials